Exchange: NASDAQ·Updated 04:20 PM EST

RCKT News

News
all
press releases
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed as Buy by Chardan Capital
Chardan Capital reaffirmed a "buy" rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday...
MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed as Buy by Chardan Capital
Chardan Capital reaffirmed a "buy" rating and issued a $11.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday...
MarketBeat
More News
Rocket Pharmaceuticals: Progress Is Encouraging, But Clinical Validation Still Matters...
SeekingAlpha
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders, today reported financial results for the third quarter ended...
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardans 10th Annual Healthcare...
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update...
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with...
Business Wire
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Zacks
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.read more...
Benzinga
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.
Stocktwits
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
Stocktwits

Advertisement|Remove ads.